Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remune in HIV-1 infection (Study 092)
NCT00002359Phase 3Completed
- Sponsor
- Immune Response Corporation
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Remune in human immunodeficiency virus infection (HIV), sponsored by Immune Response Corporation. Primary endpoint: AIDS-free survival at 148 weeks. Status: completed.
02
Drugs
Remune
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002359.